<div id="readability-page-1"><p>Nebula Research &amp; Development LLC raised its stake in shares of  Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 82.4% in the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 69,884 shares of the company's stock after purchasing an additional 31,570 shares during the period. Nebula Research &amp; Development LLC owned 0.09% of Kiniksa Pharmaceuticals International worth $1,934,000 at the end of the most recent quarter.</p><p>A number of other institutional investors have also recently made changes to their positions in the stock. Nuveen LLC acquired a new stake in shares of  Kiniksa Pharmaceuticals International in the first quarter valued at about $16,992,000.  Arrowstreet Capital Limited Partnership bought a new stake in  Kiniksa Pharmaceuticals International in the second quarter valued at approximately $20,349,000.  Qube Research &amp; Technologies Ltd increased its position in  Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research &amp; Technologies Ltd now owns 888,364 shares of the company's stock valued at $24,581,000 after purchasing an additional 653,236 shares during the period.  Acadian Asset Management LLC raised its holdings in  Kiniksa Pharmaceuticals International by 170.3% during the 1st quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock worth $22,961,000 after purchasing an additional 651,700 shares during the last quarter.  Finally, AQR Capital Management LLC raised its holdings in  Kiniksa Pharmaceuticals International by 149.1% during the 1st quarter. AQR Capital Management LLC now owns 491,761 shares of the company's stock worth $10,922,000 after purchasing an additional 294,319 shares during the last quarter. Institutional investors own  53.95% of the company's stock. </p><h2>Insider Transactions at Kiniksa Pharmaceuticals International</h2><p>In related news, CFO Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, December 8th. The shares were sold at an average price of $41.49, for a total value of $1,777,473.09. Following the completion of the sale, the chief financial officer owned 31,086 shares of the company's stock, valued at approximately $1,289,758.14. This trade represents a 57.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Eben Tessari sold 12,470 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $41.24, for a total transaction of $514,262.80. Following the sale, the chief operating officer owned 22,714 shares of the company's stock, valued at $936,725.36. This trade represents a 35.44% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 537,280 shares of company stock valued at $20,844,046. Company insiders own  53.48% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>A number of research firms have recently commented on KNSA. Weiss Ratings  reaffirmed a &#34;hold (c)&#34; rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Wells Fargo &amp; Company upped their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday, September 25th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 6th. Wedbush  reissued an &#34;outperform&#34; rating and issued a $48.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Tuesday, December 2nd. Finally, The Goldman Sachs Group upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 29th. Six research analysts have rated the stock with a Buy rating and two have assigned  a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $52.00.</p><p><b>View Our Latest Research Report on Kiniksa Pharmaceuticals International</b></p><h2>Kiniksa Pharmaceuticals International Trading Up 1.2%</h2><p>KNSA opened at $41.01 on Friday. The company has a fifty day moving average price of $39.78 and a two-hundred day moving average price of $34.33. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $42.98. The company has a market cap of $3.11 billion, a P/E ratio of 91.14 and a beta of 0.02. </p><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. During the same quarter in the prior year, the business earned ($0.18) earnings per share. The business's quarterly revenue was up 61.2% on a year-over-year basis.  On average, research analysts forecast that  Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year. </p><h2>Kiniksa Pharmaceuticals International Profile</h2> (Free Report)<p>Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Kiniksa Pharmaceuticals International</li><li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li><li>3 Recently Downgraded Stocks to Avoid in 2026</li><li>What is the Hang Seng index?  </li><li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li><li>3 Tickers Leading a Meme Stock Revival</li><li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Kiniksa Pharmaceuticals International Right Now?</h2><p>Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.</p><p>While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

KNSA

<p>Nebula Research & Development LLC increased its stake in Kiniksa Pharmaceuticals by 82.4% in Q2, owning 69,884 shares worth $1.93 million. Other institutional investors also adjusted their positions. Insider transactions included significant stock sales by CFO Mark Ragosa and COO Eben Tessari. Analysts have mixed ratings, with a consensus price target of $52.00. Kiniksa's stock is trading at $41.01, with a market cap of $3.11 billion.</p>

Nebula Research & Development LLC Has $1.93 Million Stake in Kiniksa Pharmaceuticals International, plc $KNSA